Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Cost Reimbursement

Drugs

Locations

Clinical Specialty

921-940 of 991 trials

Chronic Hepatitis Delta: Brelovitug Treatment Study

We are studying a new medication, brelovitug, for people with chronic hepatitis delta infection. The trial aims to see if it works better than waiting for treatment and to evaluate its safety.

Hepatitis D>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteHepatology

Follicular Lymphoma: Golcadomide with Rituximab Study

We are comparing a new treatment combination to standard options for patients with relapsed or refractory follicular lymphoma. The study aims to see if this combination improves survival and quality of life.

Follicular LymphomaRelapsed/Refractory Follicular Lymphoma>2 yearsConfirmation phase (III)No Placebo Investigational Medicines Cost ReimbursementHematologyOncology

Testosterone Gel for Improving Recovery in Critically Ill Patients

We are studying whether daily testosterone gel can enhance physical performance and recovery in men and women during critical illness. This trial compares the gel to a placebo to see if it helps patients recover better after ICU admission.

Invasive Mechanical VentilationEfficacy phase (II)Standard Medicines Cost ReimbursementEndocrinologyInternal Medicine

Advanced Solid Tumors: Testing IPN01195

We are studying a new medicine called IPN01195 to see how safe it is and what the best dose is for adults with advanced solid tumors. This trial aims to understand its effects on tumor activity and how it works in the body.

Advanced Solid Tumour3-6 monthsSafety phase (I)Efficacy phase (II)≤5 visits No Placebo Standard Medicines Cost ReimbursementOncology

Alzheimer's Disease: MK-2214 Study

We are testing a new medication, MK-2214, in people with early Alzheimer's disease to see if it may slow the progression of brain changes. The study will also evaluate the safety of this treatment compared to a placebo.

Alzheimer's Disease>2 yearsEfficacy phase (II)>20 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementNeurology

Chronic Heart Failure: Omecamtiv Mecarbil Study

We are testing a new medication for people with chronic heart failure and severely reduced heart function. The study aims to see if it can improve heart health outcomes compared to a placebo.

Heart Failure with Reduced Ejection Fraction>2 yearsConfirmation phase (III)11-15 visits Investigational Medicines Cost Reimbursement Partially RemoteCardiologyInternal Medicine

Refractory Schizophrenia: NaBen® with Clozapine

We are studying whether NaBen®, a new medication, can help adults with refractory schizophrenia who still have symptoms despite treatment with clozapine. The trial will also assess the safety of this combination therapy.

Treatment-resistant Schizophrenia≤3 monthsEfficacy phase (II)Confirmation phase (III)Investigational Medicines Cost ReimbursementPsychiatry

Major Depressive Disorder: CYB003 Treatment Study

We are studying the effects of a new medication, CYB003, on symptoms of major depressive disorder in adults. This trial compares its effectiveness to a placebo to see if it may help improve mood and quality of life.

Major Depressive Disorder3-6 monthsConfirmation phase (III)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemotePsychiatry

Systemic Lupus Erythematosus: CC-97540 CAR T Cell Therapy

We are studying a new CAR T cell therapy for people with active lupus who haven't responded to standard treatments. The goal is to see if it can improve symptoms and overall health.

Systemic Lupus ErythematosusLupus Nephritis>2 yearsEfficacy phase (II)11-15 visits No Placebo Investigational Medicines Cost Reimbursement Partially RemoteHematologyRheumatology

Chronic HDV Infection: Tobevibart and Elebsiran Study

We are studying a new combination therapy for people with chronic HDV infection who haven't responded to prior treatment. The goal is to see if this therapy can effectively reduce the virus and improve liver health.

Chronic Hepatitis D Virus Infection>2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementHepatologyInfectious Diseases

UTI Vaccine Study for Adults Aged 18-64

We are testing a new vaccine to see if it can safely prevent urinary tract infections caused by E. coli in adults, especially women. The study will compare its effectiveness to a placebo.

Urinary Tract Infections1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visits Standard Medicines Cost Reimbursement Partially RemoteInfectious DiseasesUrology

Endometrial Cancer: Sacituzumab Tirumotecan and Pembrolizumab Study

We are studying a combination of sacituzumab tirumotecan and pembrolizumab for people with advanced or recurrent endometrial cancer. The goal is to see if this combination works better than pembrolizumab alone.

Endometrial CarcinomaConfirmation phase (III)Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicineOncology

Low-Grade Upper Tract Urothelial Cancer: UGN-104 Treatment Study

We are studying a new treatment called UGN-104 for patients with low-grade upper tract urothelial cancer. The trial aims to see how well it reduces tumors and its safety compared to existing options.

Low-grade Upper Tract Urothelial Cancer1-2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementOncologyUrology

IgA Nephropathy: Felzartamab Infusions

We are studying the effects of felzartamab infusions on adults with IgA nephropathy to see if it helps reduce protein in urine and improve kidney function compared to a placebo.

IgA Nephropathy>2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementInternal MedicineNephrology

Alopecia Areata: Ritlecitinib Study

We are investigating whether two doses of ritlecitinib can help people aged 12 and older with alopecia areata regrow their scalp hair. The study compares the effects of the medication to a placebo.

Alopecia Areata6-12 monthsConfirmation phase (III)6-10 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteAllergologyDermatology

Severe Asthma: Verekitug (UPB-101) Study

We are studying the long-term safety and effects of verekitug in adults with severe asthma. This research aims to see how it helps manage asthma attacks and improve breathing.

Severe Asthma1-2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteAllergologyPulmonology

Rezafungin for Chronic Pulmonary Aspergillosis Treatment

We are studying whether rezafungin can effectively treat chronic pulmonary aspergillosis in adults with few treatment options. The trial will assess both the effectiveness and safety of this medication.

Chronic Pulmonary Aspergillosis6-12 monthsEfficacy phase (II)>20 visits No Placebo Standard Medicines Cost ReimbursementInfectious DiseasesPulmonology

Insomnia in Adolescents: Melatonin vs. Quetiapine

We are studying whether melatonin or low-dose quetiapine can improve sleep in adolescents with psychiatric disorders and insomnia. We’ll also look at how these treatments affect overall well-being and daily functioning.

Psychiatric Disorders and Insomnia≤3 monthsEfficacy phase (II)Confirmation phase (III)6-10 visits Standard Medicines Cost Reimbursement Partially RemotePsychiatry

Metastatic Melanoma: V940 and Pembrolizumab Study

We are studying a new treatment combining V940 with pembrolizumab for people with metastatic melanoma. The aim is to see if this combination helps improve survival compared to a placebo.

Melanoma>2 yearsEfficacy phase (II)Investigational Medicines Cost ReimbursementOncology

Head and Neck Cancer: Ficerafusp Alfa with Pembrolizumab

We are studying whether ficerafusp alfa combined with pembrolizumab can effectively treat patients with recurrent or metastatic head and neck cancer. This trial aims to find the best dose and compare its effects to a placebo.

Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma1-2 yearsEfficacy phase (II)Confirmation phase (III)Investigational Medicines Cost ReimbursementOncology

Search Clinical Trials in the European Union